ATNX: way oversold, doubling down here

Doubled down on ATNX at $5.32.

The company is down 50% today based on quarterly results and FDA rejection of their drug. However:

1. the company still has room to fight the decision

2. the company has a portfolio of other products to support its revenue

3. the company has a pipeline of other drugs in development.

Here is the link to my original analysis:

https://www.wininstocks.com/post/subscriber-alert-added-atnx-stock-to-the-portfolio-athenex-inc